Cell Line and Membrane Market Expected to Reach $10.6 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Cell Line and Membrane Market," The Cell Line and Membrane Market size was valued at $4.5 billion in 2021, and is estimated to reach $10.6 billion by 2031, growing at a CAGR of 8.8% from 2022 to 2031.

A cell line is a permanently established cell culture, which is frequently used to investigate biological processes in place of primary cells. Cell line is a general term that applies to a defined population of cells that can be maintained in culture for an extended period of time, retaining the stability of certain phenotypes and functions. It is used in a variety of applications, including the creation of biologics (recombinant proteins and monoclonal antibodies), drug screening, and gene functional investigations.   

The key factors that drive the Cell Line and Membrane Market growth are rises in the prevalence of cancer and chronic diseases. Moreover, the rise in the geriatric population, an increase in the adoption of regenerative medicines, and a surge in investments in R&D by pharmaceutical and biotechnology companies propel the growth of the cell line and membrane market. Moreover, the market is expected to experience growth during the forecast period owing to a rise in development & demand for monoclonal antibodies around the globe, a surge in vaccine production, and technological innovations in cell lines & the membrane. For instance, in April 2020, CEVEC Pharmaceuticals GmbH announced the launch of the ELEVECTA platform that is expected to produce stable cell lines for AAV (Adeno-associated viral) vector for gene therapy.

However, a strict regulatory framework coupled with the time-consuming process for the development of stable lines might restrain the growth of the market. Whereas, low-income countries lack access to basic healthcare facilities, and the increase in the risk of pandemics and communicable diseases are some of the Cell Line and Membrane Market trends which further drives the growth of market . 

The Cell Line Market is segmented on the basis of product, source, type, end user, and region. By product, the market is segmented into media & reagents, equipment, and accessories & consumables. By source, it is bifurcated into mammalian cell lines and non-mammalian cell lines. By type, the market is fragmented into recombinant cell type, hybridomas, continuous cell line, and primary cell line. By end user, the market is divided into biotech companies, academic & research institutes, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA

On the basis of product, the Cell Membrane Market is segmented into media & reagents, equipment, and accessories & consumables. In 2021, the media and reagents segment accounted for the largest share of the market. The dominance of this segment can be attributed to the rise in prevalence of cancer & chronic diseases and rise in the number of R&D activities across the world, increasing product approval and new product launches.

On the basis of source, the cell line and membrane market is segmented into mammalian cell line and non-mammalian cell line. In 2021, the mammalian cell line segment accounted for the largest share of the market. The dominance of this segment can be attributed to the rise in the demand for recombinant protein development through the mammalian cell.

On the basis of type, the market is segmented into recombinant cell type, hybridomas, continuous cell line and primary cell line. The recombinant cell line segment exhibited the highest growth in 2021, and is anticipated to lead during the forecast period owing to the rise in demand for recombinant cell lines, which owes a great deal to technological advancement in expression vector design, cell line engineering, and clone screening.

By end user, the market is divided into biotech companies, academic and research institutes, and others. The biotechnology and pharmaceutical industries segment exhibited the highest growth in 2021 and is anticipated to lead during the forecast period, owing to the rise in the demand for biotherapeutic and biosimilar drugs. The increase in the geriatric population and the rise in the prevalence of cancer are the key factors that drive the growth of the market in the upcoming years.

North America accounted for a majority of the cell line and membrane market share in 2021 and is anticipated to remain dominant during the forecast period owing to rise in the prevalence of cancer, increased use of media & reagents for cell line development, and the presence of major key players.

Asia-Pacific was the second largest contributor to the market in 2021, and is expected to register the fastest CAGR during the forecast period, owing to a rise in the prevalence of chronic diseases and an increase in the geriatric population in developing countries.

The key players that operate in the cell line and membrane market are Advanced Instruments LLC, AGC Biologics, Cytiva Lifesciences, Sartorius Cellgenix Gmbh, Premas Biotech, Selexis SA, Lonza, Samsung Biologics, PromoCell, Thermofisher Scientific Inc, Imegenex India Pvt. Ltd., and ProBioGen.

Key findings of the study

• • By product, the media and reagents segment were the highest contributor to the market in 2021
  • By source, the mammalian cell line segment was the highest contributor to the market in 2021.
  • By type, the recombinant cell line segment was the highest contributor in 2021.
  • By end user, the biotechnology and pharmaceutical industries dominated the market in 2021 and is expected to continue this trend during the forecast period.
  • By Region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.